This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAbout OCTAGAM 10%EfficacyEfficacyDMcITPSafety & TolerabilitySafety & TolerabilityDMcITPDosing & Infusion RatesDosing & Infusion Rates DMcITPSupportSupportMaterialsVideosPfizer OCTAGAM Co-Pay ProgramPfizer IGuide™Ig CompanionFrequently asked questionsRequest a representative

Coverage

Prescribing Information, including BOXED WARNINGIndicationsOCTAGAM 5%Patient Site
Dosing & Infusion Rates

Dosing and
administration

Infusion rate chart

Infusion rate calculator

Header
The first and only FDA-approved IVIg therapy to treat DM—dosed at 2 g/kg every 4 weeks1
  • The initial infusion rate should be maintained for 30 minutes, and if tolerated, the infusion rate may be gradually increased every 30 minutes to a maximum of 4 mg/kg/min (0.04 mL/kg/min) as tolerated1†
  • Patients with DM are at increased risk for thromboembolic events; monitor carefully and do not exceed an infusion rate of 0.04 mL/kg/min1
  • ​​Ensure that patients with pre-existing renal insufficiency are not volume depleted. For 
    patients at risk of renal dysfunction or thromboembolic events, administer OCTAGAM 10% at the minimum infusion rate practicable, not to exceed 3.3 mg/kg/min (0.03 mL/kg/min). Discontinue OCTAGAM 10% if renal function deteriorates1
  • The majority of OCTAGAM 10% infusions were given over 2 days in the study2
Dose and rate of administration based on clinical study data.Monitor the patient carefully throughout the infusion. Certain adverse reactions may be related to the rate of infusion. Slowing or stopping the infusion usually allows the symptoms to disappear promptly. Once the symptoms subside, the infusion may then be resumed at a lower rate1.Example infusion ramp-up schedule for an adult patient with DM
  • OCTAGAM 10% should be started at 1 mg/kg/min and continued at the infusion rates 
    stated here, if tolerated1
  • The example shown here illustrates an infusion ramp-up schedule for a 80-kg patient 
    with DM using rates of 1, 2, and 4 mg/kg/min
  • For patients at risk of renal dysfunction or thromboembolic events, administer 
    OCTAGAM 10% at the minimum infusion rate practicable, not to exceed 3.3 mg/kg/min 
    (0.03 mL/kg/min). Discontinue OCTAGAM 10% if renal function deteriorates1
Dose and rate of administration based on clinical study data.Reference:Data on file. Octapharma USA Inc.
The OCTAGAM 10% [Immune Globulin Intravenous (Human) liquid] infusion rate chart below will help you calculate the appropriate infusion rate for an adult patient with DM1
  • For patients with DM: 2 g/kg divided in equal doses given over 2-5 consecutive days every 4 weeks
  • Patients with dermatomyositis are at increased risk for thromboembolic events; monitor carefully and do not exceed an infusion rate of 4 mg/kg/min (0.04 mL/kg/min)
  • For patients judged to be at risk for developing renal dysfunction or thromboembolic events, administer OCTAGAM 10% at the minimum infusion rate practicable, not to exceed 0.03 mL/kg/min (3.33 mg/kg/min)—equal to 2.0 mL/kg/hr (200 mg/kg/hr)
Download the OCTAGAM 10% DM Infusion Rate Chart
LoadingReference:Octagam 10%. Prescribing information. Octapharma USA Inc.; 2022.
Next
Start again Return to previous
Step 1: Choose indication1
With this calculator, you can determine:
  • infusion ramp-up rate to program into an IV infusion pump
  • estimated time to complete the infusion
Choose an indication:
Step 2: Enter patient's body weight and OCTAGAM 10% dose for this infusion1

Patient with DM one field from each section below needs to be completed before proceeding to the next step.

Enter patient’s body weight
 lb
OR
 kg
andEnter patient’s OCTAGAM 10% dose for this infusion*
 g
OR
 mL
Calculated answer: Recommended ramp-up infusion rates1

Patient with DM based on patient’s body weight of {{weight}} kg and a dose of {{dose}} g of OCTAGAM 10%, see below for recommended ramp-up infusion rates

First 30 minutes

0.01 mL/kg/min
(1 mg/kg/min)

{{doseGrams.firstInterval}}

mL/hr

Next 30 minutes

(if previous is tolerated)

0.02 mL/kg/min
(2 mg/kg/min)

{{doseGrams.secondInterval}}

mL/hr

Maximum Infusion Rate

(if previous is tolerated)

0.04 mL/kg/min
(4 mg/kg/min)

≤{{doseGrams.maxInfusion}}

mL/hr

Estimated time to infuse {{dose}} g ({{doseMl}} mL) is {{infusionTime}}

(if the rates above are tolerated by the patient)

Step 2: Enter patient's body weight and OCTAGAM 10% dose for this infusion1

Patient with cITP one field from each section below needs to be completed before proceeding to the next step.

Enter patient’s body weight
 lb
OR
 kg
andEnter patient’s OCTAGAM 10% dose for this infusion*
 g
OR
 mL
Calculated answer: Recommended ramp-up infusion rates1

Patient with cITP based on patient’s body weight of {{weight}} kg and a dose of {{dose}} g of OCTAGAM 10%, see below for recommended ramp-up infusion rates

First 30 minutes

0.01 mL/kg/min
(1 mg/kg/min)

{{doseGrams.firstInterval}}

mL/hr

Next 30 minutes

(if previous is tolerated)

0.02 mL/kg/min
(2 mg/kg/min)

{{doseGrams.secondInterval}}

mL/hr

Next 30 minutes

(if previous is tolerated)

0.04 mL/kg/min
(4 mg/kg/min)

{{doseGrams.thirdInterval}}

mL/hr

Next 30 minutes

(if previous is tolerated)

0.08 mL/kg/min
(8 mg/kg/min)

{{doseGrams.fourthInterval}}

mL/hr

Maximum Infusion Rate

(if previous is tolerated)

0.12 mL/kg/min
(12 mg/kg/min)

≤{{doseGrams.maxInfusion}}

mL/hr

Estimated time to infuse {{dose}} g ({{doseMl}} mL) is {{infusionTime}}

(if the rates above are tolerated by the patient)

Calculate
Start again Return to previous

* Daily infusion dose, not the total infusion dose, which may be split over 2-5 days.

New calculation
Start again Return to previous
Reference:Octagam 10%. Prescribing information. Octapharma USA Inc.; 2022.
Dosing & Infusion Rates  DM efficacy data Review now DM safety and tolerability data Review data
OCTAGAM 10% DM clinical results video Watch hereLoading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-OTG-USA-0273

Indications and Usage

OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.

Please click here for Full Prescribing Information, including BOXED WARNING.

Indications and Usage OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults. Please click here for Full Prescribing Information, including BOXED WARNING.
IMPORTANT SAFETY
INFORMATION WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
  • Thrombosis may occur with immune globulin intravenous (IgIV) products, including OCTAGAM 10% liquid. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IgIV products, including OCTAGAM 10% liquid. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IgIV products containing sucrose. OCTAGAM 10% liquid does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer OCTAGAM 10% liquid at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Dosing and Administration Patients with dermatomyositis are at increased risk for thromboembolic events; monitor carefully and do not exceed an infusion rate of 0.04 mL/kg/min. ContraindicationsOCTAGAM 10% liquid is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.Warnings and PrecautionsOCTAGAM 10% liquid may cause hypersensitivity in patients with a corn allergy. OCTAGAM 10% liquid contains maltose, which is derived from corn. Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure. Falsely elevated blood glucose readings may occur during and after the infusion of OCTAGAM 10% liquid with testing by some glucometers and test strip systems. Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving OCTAGAM 10% liquid. Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to treatment with OCTAGAM 10% liquid. Risk factors for hemolysis include high doses and non–O-blood group. Closely monitor patients for hemolysis and hemolytic anemia. Aseptic meningitis syndrome may occur in patients receiving OCTAGAM 10% liquid, especially with high doses or rapid infusion. Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). OCTAGAM 10% liquid is made from human plasma and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent. Adverse Reactions cITP - The most common adverse reactions reported in >5% of study subjects were headache, fever, and increased heart rate. DM - The most common adverse reactions reported in >5% of study subjects were headache, fever, nausea, vomiting, increased blood pressure, chills, musculoskeletal pain, increased heart rate, dyspnea, and infusion site reactions.You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.OCTAGAM® is a registered trademark of Octapharma AG.Please click here for Full Prescribing Information, including BOXED WARNING.INDICATIONS AND USAGEOCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.